Lucentis (ranibizumab) plus laser treatment for DME raises bar for new therapies
A double blind Phase III trial in 691 patients has reported that 0.5mg Lucentis plus prompt or deferred laser therapy had a significant improvement in… Read More »Lucentis (ranibizumab) plus laser treatment for DME raises bar for new therapies